• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Tectonic Therapeutic Inc.

    3/9/26 5:21:48 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    S-8 POS 1 d119719ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 9, 2026

    Registration No. 333-293899

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Amendment No. 1 to

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Tectonic Therapeutic, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-0710585

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    490 Arsenal Way

    Suite 200

    Watertown, MA

      02472
    (Address of Principal Executive Offices)   (Zip Code)

    2024 Equity Incentive Plan

    2024 Employee Stock Purchase Plan

    (Full titles of the plans)

    Daniel Lochner

    Chief Financial Officer

    490 Arsenal Way

    Suite 200

    Watertown, MA 02472

    (339) 666-3320

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Divakar S. Gupta

    Brandon Fenn

    Minkyu Park

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    (212) 479-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated Filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Amendment No. 1 to the Registration Statement is being filed solely for the purpose of including an updated consent of Deloitte & Touche LLP as Exhibit 23.1 in order to update the date of the consent from February 27, 2026, to February 26, 2026, and to update the audit report date referenced therein from February 27, 2026, to February 26, 2026. No changes have been made to the prospectus constituting Part I of the Registration Statement, and, therefore, it has been omitted. Accordingly, the Amendment consists solely of the facing page, this explanatory note, Part II of the Registration Statement, the signatures, the index to exhibits and the filed exhibits and is not intended to amend or delete any part of the Registration Statement except as specifically noted herein.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3.

    INCORPORATION OF DOCUMENTS BY REFERENCE.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

    (a) Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 26, 2026;

    (b) Current Report on Form 8-K, which was filed with the Commission on February 24, 2026 (except that, with respect to the foregoing Current Report, any portions thereof which are furnished and not filed shall not be deemed incorporated by reference); and

    (b) the description of the Registrant’s common stock in the Registrant’s registration statement on Form 8-A filed with the Commission on June  11, 2018, including any amendments or reports filed for the purpose of updating such description, including as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

    All documents, reports and definitive proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    ITEM 8.

    EXHIBITS.

     

    Exhibit
    Number
      

    Description

      4.1*    Fourth Amended and Restated Certificate of Incorporation, as amended through June  20, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No.  001-38537), filed with the Commission on August 14, 2024).
      4.2*    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 25, 2018).
      5.1*    Opinion of Cooley LLP.
     23.1    Consent of Deloitte & Touche LLP, independent registered public accounting firm of Tectonic Therapeutic, Inc.
     23.2*    Consent of Cooley LLP. Reference is made to Exhibit 5.1.

     

    1


    Exhibit
    Number
      

    Description

     24.1*    Power of Attorney. Reference is made to the signature page hereto.
     99.1*    Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 20, 2024).
     99.2*    Forms of Option Grant Notice, Option Agreement and Notice of Exercise under Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 20, 2024).
     99.3*    Tectonic Therapeutic, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the Commission on June 20, 2024).
    107*    Filing Fee Table.

     

    *

    Previously filed.

     

    ITEM 9.

    UNDERTAKINGS.

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement; and

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    2


    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on March 9, 2026.

     

    TECTONIC THERAPEUTIC, INC.
    By  

    /s/ Alise Reicin

      Alise Reicin
      President and Chief Executive Officer

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Alise Reicin

    Alise Reicin

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      March 9, 2026

    /s/ Daniel Lochner

    Daniel Lochner

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      March 9, 2026

    *

    Terrance McGuire

       Director   March 9, 2026

    *

    Phillip B. Donenberg

       Director   March 9, 2026

    *

    Timothy A. Springer

       Director   March 9, 2026

    *

    Praveen Tipirneni

       Director   March 9, 2026

    *

    Stefan Vitorovic

       Director   March 9, 2026
    *By:   /s/ Alise Reicin
     

    Alise Reicin

    Attorney-in-fact

     

    4

    Get the next $TECX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    10/20/2025$101.00Overweight
    Wells Fargo
    9/3/2025$80.00Outperform
    Oppenheimer
    7/21/2025$64.00Buy
    Truist
    6/11/2025$76.00Outperform
    Raymond James
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    More analyst ratings

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Executive Officer Reicin Alise bought $52,750 worth of shares (2,500 units at $21.10) (SEC Form 4)

    4/A - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    3/5/26 4:30:32 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Reicin Alise bought $52,750 worth of shares (2,500 units at $21.10), increasing direct ownership by 1% to 237,547 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/12/26 4:15:09 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Lochner Daniel bought $129,660 worth of shares (6,000 units at $21.61), increasing direct ownership by 23% to 32,044 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/11/26 5:32:12 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    SEC Filings

    View All

    SEC Form S-8 POS filed by Tectonic Therapeutic Inc.

    S-8 POS - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    3/9/26 5:21:48 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Tectonic Therapeutic Inc.

    S-8 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    2/27/26 5:28:58 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    2/26/26 4:26:23 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tectonic Therapeutic to Participate in March Investor Conferences

    WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026. TD Cowen 46th Annual Health Care Conference  Date:March 4, 2026Time:11:10 AM ESTLocation:Boston, MAFormat:Fireside ChatPresenters:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link  Leerink Global Healthcare Conference  Date:March 11, 2026Time:1:40 PM ESTLocation:M

    3/2/26 8:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF") in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT")TX45 advanced into Phase 2 clinical trial in February 2026 with first site activated and opened for screening patients with Pulmonary Hypertension associate

    2/26/26 4:17:48 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Tectonic Therapeutic with a new price target

    Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $101.00

    10/20/25 8:03:48 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Tectonic Therapeutic with a new price target

    Oppenheimer initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $80.00

    9/3/25 8:39:51 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Tectonic Therapeutic with a new price target

    Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00

    7/21/25 8:39:42 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Ruddy Marcella K. sold $300,000 worth of shares (10,000 units at $30.00), decreasing direct ownership by 13% to 69,747 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    3/9/26 6:15:19 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Mcnamara Peter sold $188,935 worth of shares (6,262 units at $30.17) and exercised 2,715 shares at a strike of $3.36, decreasing direct ownership by 6% to 55,285 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    3/9/26 6:12:18 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Reicin Alise was granted 76,500 shares, increasing direct ownership by 33% to 311,547 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    3/5/26 5:47:24 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

    SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    11/14/24 4:05:11 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/28/24 6:08:43 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/24/24 5:12:09 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Financials

    Live finance-specific insights

    View All

    Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

    TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

    1/30/25 6:30:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

    Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

    11/7/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

    TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

    8/14/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care